Serina Therapeutics, Inc. — Form 8-K
Filed September 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Serina's independent Safety Monitoring Committee approved advancement of SER-252 (long-acting apomorphine for advanced Parkinson's disease) from Cohort 1 to Cohort 2 after blinded review. Cohort 1 (8 patients, lowest dose) showed sustained pharmacokinetic profile consistent with design and sustained motor function improvements on exploratory measures; safety/tolerability supported escalation. Topline single-ascending-dose data expected H1 2027.
Why this rating
Early-stage clinical milestone in lead asset for $21.8M company. SMC clearance de-risks program path and validates core mechanism; small patient cohort and blinded design limit predictive power but represent genuine go/no-go checkpoint.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit.
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.68 ▲ 7.36% | at our read · unknown $2.50 | +10 min · unknown $2.50 ▲ 0.00% | +30 min · unknown $2.50 ▲ 0.00% | +1 hr · unknown $2.50 ▲ 0.00% | +4 hrs pending |
The stock had already moved -6.86% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; sessions other than regular hours are labeled. Not investment advice. How accurate are our calls? →
See more from September 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.